Global Information
회사소개 | 문의 | 비교리스트

인테그린 베타 7 : 파이프라인 리뷰

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Drugs In Development, 2021

리서치사 Global Markets Direct
발행일 2021년 12월 상품코드 365737
페이지 정보 영문 77 Pages 배송안내
가격
US $ 3,500 ₩ 4,459,000 PDF (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,000 ₩ 8,919,000 PDF (Site License) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 10,500 ₩ 13,379,000 PDF (Global License) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


인테그린 베타 7 : 파이프라인 리뷰 Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Drugs In Development, 2021
발행일 : 2021년 12월 페이지 정보 : 영문 77 Pages

본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

인테그린 베타 7(Integrin Beta 7)을 표적으로 한 치료제 개발 파이프라인 현황과 최신 업데이트에 의한 각 개발 단계 비교 분석, 기업이나 연구기관이 개발중인 치료제, 치료제 평가, 후기 단계 및 중지된 프로젝트 관련 정보 등을 최신 뉴스 및 발표와 함께 전해드립니다.

서론

  • 조사 범위

인테그린 베타 7 개요

치료제 개발

  • 개발중인 제품 : 개발 단계별
  • 개발중인 제품 : 치료 영역별
  • 개발중인 제품 : 증상별
  • 기업에서 개발중인 제품

치료제 평가

  • 작용기전별
  • 투여 경로별
  • 분자 종류별

치료제 개발 참여 기업

  • Genentech Inc
  • Protagonist Therapeutics Inc
  • Takeda Pharmaceutical Company Ltd
  • Viriom Inc

치료제 개요

휴지 상태인 프로젝트

개발이 중지된 제품

주요 뉴스 및 프레스 릴리스

  • 주요 뉴스 및 프레스 릴리스

부록

도표

LSH 17.10.20

List of Tables

List of Tables

  • Number of Products under Development by Stage of Development, 2021
  • Number of Products under Development by Therapy Areas, 2021
  • Number of Products under Development by Indication, 2021
  • Number of Products under Development by Companies, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Companies, 2021 (Contd..1)
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Pipeline by Aviara Pharmaceuticals Inc, 2021
  • Pipeline by C4X Discovery Holdings Plc, 2021
  • Pipeline by DiCE Molecules SV Inc, 2021
  • Pipeline by Genentech USA Inc, 2021
  • Pipeline by Gilead Sciences Inc, 2021
  • Pipeline by Morphic Therapeutic Inc, 2021
  • Pipeline by Polpharma Biologics SA, 2021
  • Pipeline by Progenity Inc, 2021
  • Pipeline by Protagonist Therapeutics Inc, 2021
  • Pipeline by Takeda Pharmaceutical Co Ltd, 2021
  • Pipeline by Zealand Pharma AS, 2021
  • Dormant Projects, 2021
  • Discontinued Products, 2021

List of Figures

List of Figures

  • Number of Products under Development by Stage of Development, 2021
  • Number of Products under Development by Therapy Areas, 2021
  • Number of Products under Development by Top 10 Indications, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021

Summary:

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) pipeline Target constitutes close to 12 molecules. The latest report GMDHC3038TDB - Integrin Beta 7 - Drugs In Development, 2021, outlays comprehensive information on the Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Integrin beta-7 is an integrin protein encoded by the ITGB7 gene. It interacts with the cell surface adhesion molecules MADCAM1 which is normally expressed by the vascular endothelium of the gastrointestinal tract. Interactions involve the tripeptide L-D-T in MADCAM1, and L-D-V in fibronectin. It binds to HIV-1 gp120 that allows the virus to enter GALT (major trigger of AIDS disease). The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 2, 4 and 3 respectively. Report covers products from therapy areas Gastrointestinal, Immunology and Infectious Disease which include indications Inflammatory Bowel Disease, Crohn's Disease (Regional Enteritis), Ulcerative Colitis, Celiac Disease, Eosinophilic Esophagitis, Graft Versus Host Disease (GVHD), Human Immunodeficiency Virus (HIV) Infections (AIDS), Inflammation and Pouchitis.

Furthermore, this report also reviews key players involved in Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7)
  • The report reviews Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics

Reasons to Buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7)Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Overview
  • Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Companies Involved in Therapeutics Development
  • Aviara Pharmaceuticals Inc
  • C4X Discovery Holdings Plc
  • DiCE Molecules SV Inc
  • Genentech USA Inc
  • Gilead Sciences Inc
  • Morphic Therapeutic Inc
  • Polpharma Biologics SA
  • Progenity Inc
  • Protagonist Therapeutics Inc
  • Takeda Pharmaceutical Co Ltd
  • Zealand Pharma AS
  • Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Drug Profiles
  • etrolizumab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • GS-1427 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • MORF-057 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PN-943 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PTG-100 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Antagonize Integrin Alpha 4 Beta 1 and Alpha 4 Beta 7 for Inflammatory Bowel Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Antagonize Integrin Alpha 4 Beta 7 for Inflammatory Bowel Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Antagonize Integrin Alpha4 and Beta7 for Inflammatory Bowel Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • vedolizumab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • vedolizumab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • vedolizumab biosimilar - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ZP-10000 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Dormant Products
  • Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Discontinued Products
  • Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Product Development Milestones
  • Featured News & Press Releases
  • Sep 07, 2021: Protagonist Therapeutics appoints Scott Plevy, M.D., executive vice president and therapeutic head, gastroenterology
  • Jul 09, 2021: Morphic reports new data from positive phase 1 study of MORF-057, oral integrin inhibitor candidate for IBD
  • Jul 02, 2021: Morphic Therapeutic to host analyst and investor call on July 9, 2021
  • May 28, 2021: Morphic Therapeutic to present positive phase 1 data for MORF-057 at ECCO'21 Virtual Congress
  • Mar 01, 2021: Morphic reports positive interim results from single ascending dose phase 1 clinical trial of MORF-057
  • Feb 22, 2021: Morphic Therapeutic to host analyst and investor call on March 1, 2021
  • Jan 19, 2021: Ready-to-use self-injectable formulation of ENTYVIO (vedolizumab) now available for Canadians for the maintenance treatment of moderately to severely active Crohn's disease and ulcerative colitis
  • Dec 09, 2020: Takeda's pipeline including vedolizumab has potential to contribute significantly to revenue growth over next decade
  • Oct 13, 2020: Takeda reports positive interim data from trial of Entyvio
  • Oct 12, 2020: Morphic announces presentation of new data supporting development of MORF-057 at UEG Week Virtual 2020
  • Sep 23, 2020: Morphic Therapeutic announces first healthy volunteers dosed in Phase 1 clinical trial of MORF-057
  • Sep 02, 2020: Update on the U.S. Development Program for the investigational subcutaneous formulation of ENTYVIO (vedolizumab) as a maintenance therapy in adults with moderate to severe Ulcerative Colitis
  • Aug 11, 2020: Roche announces mixed Phase III results of etrolizumab
  • Jun 23, 2020: Takeda receives U.S. FDA approval to manufacture ENTYVIO (vedolizumab) drug substance at manufacturing facility in Brooklyn Park, Minnesota
  • May 08, 2020: European commission approves subcutaneous formulation of Entyvio (Vedolizumab) for use as maintenance therapy in adults with moderately to severely active Ulcerative Colitis or Crohn's Disease
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
Back to Top
전화 문의
F A Q